BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioNJ - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://bionj.org
X-WR-CALDESC:Events for BioNJ
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240306T120000
DTEND;TZID=America/New_York:20240306T130000
DTSTAMP:20260504T120009
CREATED:20240130T152008Z
LAST-MODIFIED:20240130T152134Z
UID:10742-1709726400-1709730000@bionj.org
SUMMARY:Integrating AI and Robotics to Discover New Drugs Faster
DESCRIPTION:FREE Webinar: Integrating AI and Robotics to Discover New Drugs Faster \n\n\n\nWednesday\, March 6\, 2024 | 12:00 p.m.-1:00 p.m. \n\n\n\n\nRegister Today for FREE!\n\n\n\n\nJoin us for this one-hour webinar where experts will use Iktos’ AI-driven platform to explore the synergy between artificial intelligence and robotics in the design and synthesis of novel molecules for drug discovery and optimization.  \n\n\n\nFrom handling diverse molecules\, reactions and exit vectors to optimizing reactants\, procedures and the number of steps\, this groundbreaking approach is poised to reshape the future of drug discovery.  \n\n\n\nBy streamlining research processes and addressing current weaknesses related to sub-optimal workflows and time-consuming manual tasks\, AI solutions have the potential to deliver a drug candidate within 24 months with just two chemists and one robot\, a significant reduction compared to the conventional requirement of 10 people and 30 months. \n\n\n\nInvite your entire Team to attend this FREE webinar\, including your scientists\, researchers\, R&D leads and business development professionals! \n\n\n\nSpeakers: \n\n\n\n\n\n\n\n\nQuentin Perron\, Ph.D.Co-Founder & Chief Scientific Officer\, Iktos \n\n\n\nAfter completing his post-doc fellowship at UCLA where Dr. Perron worked on the total synthesis of Brasillicardin A\, a complex natural molecule known for having a potent immunosuppressive activity\, he was a medicinal chemist in CNS indications at Laboratoires Servier. He later switched to data science and chemoinformatics at Quinten\, a company specialized in data science services. In 2016\, with his business partners Yann Gaston-Mathé and Nicolas Do Huu\, Dr. Perron co-founded Iktos\, a start-up company developing AI technologies for new drug design. \n\n\n\n\n\n\n\n\n\nFranck Le Vaillant\, Ph.D.\, MBASenior Scientist & Deputy Lab Head\, Iktos \n\n\n\nUpon completion of his Ph.D.\, Dr. Le Vaillant became a SNF-postdoctoral fellow to the Max-Planck-Institute für Kohlenforschung in Mülheim an der Ruhr where he developed Ni-catalyzed C-O bond formations using nitrous oxide. He later started the Labcom HitCat\, a joint lab between the company Seqens and the group of Prof. Géraldine Masson (CNRS). Dr. Le Vaillant joined Iktos in July 2022\, where he works on the installation\, development and utilization of the Iktos Robotics Platform for Drug Discovery. \n\n\n\n\n\n\n\n\nWe hope to see you on March 6\, 2024 for this FREE educational webinar.
URL:https://bionj.org/event/integrating-ai-and-robotics-to-discover-new-drugs-faster/
CATEGORIES:BioNJ Event,Entrepreneurs-Exchange
ATTACH;FMTTYPE=image/png:https://bionj.org/wp-content/uploads/2023/08/HECT-Best-Practices-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240327T120000
DTEND;TZID=America/New_York:20240327T130000
DTSTAMP:20260504T120009
CREATED:20240220T153351Z
LAST-MODIFIED:20240315T150421Z
UID:10856-1711540800-1711544400@bionj.org
SUMMARY:Top Priorities for Life Sciences CFOs in 2024: A Life Sciences CFO Roundtable
DESCRIPTION:FREE Webinar: Top Priorities for Life Sciences CFOs in 2024: A Life Sciences CFO Roundtable \n\n\n\nQualifies for 1.0 CPE Credit in Specialized Knowledge. \n\n\n\nWednesday\, March 27\, 2024 | 12:00 p.m.-1:00 p.m. \n\n\n\n\nRegister Today for FREE!\n\n\n\n\nJoin BioNJ and BDO on Wednesday\, March 27 for a roundtable discussion with life sciences CFOs about opportunities and risks facing the industry in 2024. \n\n\n\nThe webinar will discuss BDO’s 2024 Life Sciences CFO Outlook Survey\, which polled life sciences CFOs on their expectations for 2024. Below are some of the key issues this webcast will address. \n\n\n\n\nReview how life sciences CFOs are adjusting their cash management and investing strategies in response to ongoing economic volatility.\n\n\n\nDiscuss what tax strategies life sciences CFOs are pursuing to improve their financial standing — and what opportunities they may be missing.\n\n\n\nDescribe the treatments and drug modalities that life sciences CFOs will be prioritizing in 2024.\n\n\n\nExplain how life sciences organizations are addressing generative AI risks and concerns\, especially those related to data privacy.\n\n\n\n\nWho should attend: Private and Public Company Controllers\, Vice Presidents of Finance\, CFOs\, R&D Company CEOs\, Finance Team Members and Legal Counsel and others who are interested in the life sciences ecosystem. \n\n\n\nPanelists: \n\n\n\n\n\n\n\n\nAmit BhallaExecutive Vice President & Chief Financial Officer\, Sampled \n\n\n\nMr. Bhalla has more than 25 years of Wall Street and healthcare industry experience. His background in finance\, strategy and business development includes experience in equity investing as well as sourcing\, negotiating and integrating transformational and tuck-in M&A. Most recently\, Mr. Bhalla served as Senior Healthcare Analyst at Lord\, Abbett & Co. with responsibility for investments across all healthcare verticals in seven Lord Abbett funds. \n\n\n\n\n\n\n\n\n\nMike MaddenChief Financial Officer\, Lumanity \n\n\n\nMr. Madden is responsible for the Lumanity’s financial operations and functions. This includes financial strategy\, financial performance management\, capital allocation\, financial services\, controllership\, tax\, treasury and corporate strategy. Mr. Madden joined Lumanity in 2023 as an experienced finance leader\, with over 20 years of global finance and transformation experience. He possesses a proven track record of success with Fortune 250 financial institutions\, large multinational\, public\, and private equity backed companies. \n\n\n\n\n\n\n\n\n\nHarry PalminExperienced CFO \n\n\n\nMr. Palmin has a successful track record of building\, financing and operating public/private life sciences companies for 25 years\, having taken 3 companies public. He served as CFO at Acer Therapeutics from 2016 until the sale to Zevra Therapeutics in November 2023. Mr. Palmin took Acer public in 2017 achieving a $330 million peak market capitalization and raised $172 million in pursuit of Acer’s drug development and commercial objectives culminating in OLPRUVA® approval in December 2022. \n\n\n\n\n\n\n\n\n\nSarah RomanoCPA\, Chief Financial Officer\, First Wave BioPharma \n\n\n\nBefore joining First Wave BioPharma in March 2022\, Ms. Romano held the position of Chief Financial Officer at Kiora Pharmaceuticals\, a clinical-stage specialty pharmaceutical company focused on ophthalmic disease treatments\, from February 2017 to February 2022. Earlier\, she served as Corporate Controller at Kiora Pharmaceuticals from August 2016 to January 2017. Prior to that\, Ms. Romano worked as an Assistant Controller at TechTarget and as Corporate Controller at Bowdoin Group\, a healthcare-oriented executive recruitment firm. \n\n\n\n\n\n\n\n\n\nModerator \n\n\n\nDouglas E. Gustin\, CPAAssurance Principal\, BDO \n\n\n\nMr. Gustin has over 20 years of combined experience in public and private accounting working primarily with middle-market companies in technology\, manufacturing and life sciences industries. His client service experience includes working on SEC engagements\, including accelerated and large accelerated issuers as well as private equity\, venture backed and family-owned businesses. Mr. Gustin has extensive experience working with other BDO International member firms. \n\n\n\n\n\n\n\n\nThe life sciences industry is changing. Learn what opportunities and risks could await life sciences companies in 2024 and how to plan ahead. \n\n\n\nWe hope to see you on March 27\, 2024 for this FREE educational webinar.
URL:https://bionj.org/event/bdos-life-sciences-cfo-outlook-survey-live-sciences-resets-and-refocuses/
CATEGORIES:BioNJ Event,Entrepreneurs-Exchange
ATTACH;FMTTYPE=image/png:https://bionj.org/wp-content/uploads/2023/08/HECT-Best-Practices-1.png
END:VEVENT
END:VCALENDAR